论文部分内容阅读
目的观察长春瑞滨联合顺铂二线治疗晚期乳腺癌的疗效和不良反应。方法收集经紫杉类和/或蒽环类化疗后复发晚期乳腺癌病人39例,应用长春瑞滨联合顺铂方案化疗。用药方案:长春瑞滨25mg/m2静脉滴注,d1、8,顺铂75mg/m2,静脉滴注,分割为2~4d,21d为1周期。按照WHO实体瘤疗效评价标准近期疗效评估,同时按照NIH CTC 3.0版标准进行毒性分级。结果 39例患者均进行了疗效评价,CR1例,PR20例,SD10例,PD8例,总有效率为53.8%,既往应用紫杉类和/或蒽环类药物对疗效无明显影响(P>0.05),主要不良反应为白细胞减少和恶心呕吐。无治疗相关性死亡。结论长春瑞滨联合顺铂治疗二线治疗晚期乳腺癌疗效确定,不良反应可耐受。
Objective To observe the efficacy and adverse reactions of vinorelbine combined with cisplatin in the treatment of advanced breast cancer. Methods Thirty-nine patients with recurrent breast cancer after chemotherapy of taxane and / or anthracycline were collected and treated with vinorelbine plus cisplatin. Drug regimen: Vinorelbine 25mg / m2 intravenous drip, d1,8, cisplatin 75mg / m2, intravenous infusion, divided into 2 ~ 4d, 21d for a cycle. According to the recent WHO curative effect evaluation criteria for solid tumors, toxicological grading was conducted according to the NIH CTC 3.0 version. Results All the 39 patients were evaluated with CR1, PR20, SD10 and PD8. The total effective rate was 53.8%. Previous application of taxanes and / or anthracyclines had no significant effect on the therapeutic effect (P> 0.05 ), The main adverse reactions were leukopenia and nausea and vomiting. No treatment-related deaths. Conclusion Vinorelbine plus cisplatin in the treatment of second-line treatment of advanced breast cancer to determine the efficacy of adverse reactions can be tolerated.